140 related articles for article (PubMed ID: 11958981)
1. Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.
Haning H; Niewöhner U; Schenke T; Es-Sayed M; Schmidt G; Lampe T; Bischoff E
Bioorg Med Chem Lett; 2002 Mar; 12(6):865-8. PubMed ID: 11958981
[TBL] [Abstract][Full Text] [Related]
2. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.
Haning H; Niewöhner U; Schenke T; Lampe T; Hillisch A; Bischoff E
Bioorg Med Chem Lett; 2005 Sep; 15(17):3900-7. PubMed ID: 15993055
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Hallén K; Wiklund NP; Gustafsson LE
Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
[TBL] [Abstract][Full Text] [Related]
5. Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Sui Z; Guan J; Macielag MJ; Jiang W; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Clancy J
J Med Chem; 2002 Sep; 45(19):4094-6. PubMed ID: 12213052
[TBL] [Abstract][Full Text] [Related]
6. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Rosen RC; Shaw JW
Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
[No Abstract] [Full Text] [Related]
9. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
Filippi S; Morelli A; Sandner P; Fibbi B; Mancina R; Marini M; Gacci M; Vignozzi L; Vannelli GB; Carini M; Forti G; Maggi M
Endocrinology; 2007 Mar; 148(3):1019-29. PubMed ID: 17138653
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
Pissarnitski D
Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.
Coates WJ; Connolly B; Dhanak D; Flynn ST; Worby A
J Med Chem; 1993 May; 36(10):1387-92. PubMed ID: 8388468
[TBL] [Abstract][Full Text] [Related]
12. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
13. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
[TBL] [Abstract][Full Text] [Related]
14. [Chronic treatment with PDE-5 inhibitors is there anything more than treating erectile dysfunction?].
Vela Navarrete R; García Cardoso JV; López Farre A; Quesada Romero P; Pardo Montero M
Actas Urol Esp; 2007 Mar; 31(3):179-84. PubMed ID: 17658146
[No Abstract] [Full Text] [Related]
15. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason HJ; Wu X; Wang J; Chong S; Dorough G; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Adam L; Krupinski J; Macor JE
J Med Chem; 2001 Mar; 44(7):1025-7. PubMed ID: 11297448
[No Abstract] [Full Text] [Related]
16. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
19. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
Corbin JD; Beasley A; Blount MA; Francis SH
Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
[TBL] [Abstract][Full Text] [Related]
20. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
